NCT00079313View on ClinicalTrials.gov

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 14, 2004

Primary Completion Date

December 30, 2006

Study Completion Date

October 25, 2010

Conditions
Chronic Myelomonocytic LeukemiaChronic Myelogenous Leukemia
Interventions
DRUG

Imatinib

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00079313 - Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter